Clinical Trials Using Ceritinib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Ceritinib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-9 of 9
  • Biomarker / ALK Inhibitor Combinations in Treating Patients with Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)

    This National Cancer Institute (NCI)-NRG ALK Protocol phase II trial studies how well a combination of different biomarker / ALK inhibitors work in treating patients with stage IV ALK positive non-squamous non-small cell lung cancer. Lorlatinib, ceritinib, alectinib, brigatinib, ensartinib, and crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pemetrexed, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether a combination of biomarker / ALK inhibitors or chemotherapy may work better in treating patients with ALK positive non-squamous non-small cell lung cancer.
    Location: 383 locations

  • Ceritinib and Trametinib in Treating Patients with ALK Positive Stage IIIB-IV Non-small Cell Lung Cancer

    This phase I / II trial studies the best dose and side effects of ceritinib and trametinib in treating patients with ALK positive stage IIIB-IV non-small cell lung cancer. Ceritinib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

    A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
    Location: 4 locations

  • Ceritinib and Docetaxel in Treating Patients with Stage IIIB / IV ALK-Negative and EGFR Wild-Type Non-small Cell Lung Cancer

    This phase I trial studies the best dose and side effects of ceritinib and docetaxel in treating patients with stage IIIB / IV ALK-negative and EGFR wild-type non-small cell lung cancer. Ceritinib and docetaxel may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving ceritinib and docetaxel may work better in treating patients with non-small cell lung cancer.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Ceritinib in Treating Participants with Stage 3C / D / 4 Unresectable Melanoma

    This phase II trial studies how well ceritinib works in treating participants with stage 3C / D / 4 melanoma that cannot be removed by surgery. Ceritinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Next Generation Personalized Neuroblastoma Therapy with Ribociclib and Ceritinib, Trametinib, or HDM2 Inhibitor HDM201 in Treating Younger Patients with High-Risk Neuroblastoma

    This phase I trial studies the side effects and best dose of ribociclib when given together with ceritinib, and HDM2 inhibitor HDM201, and to also see how well ribociclib and ceritinib, trametinib, or HDM2 inhibitor HDM201 work in treating patients with high-risk neuroblastoma. Ribociclib, ceritinib, trametinib, and HDM2 inhibitor HDM201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Assigning patients to different treatment groups with ribociclib and ceritinib, trametinib, or HDM2 inhibitor HDM201 based on genetic testing may work better in treating neuroblastoma.
    Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

  • Ceritinib and Stereotactic Body Radiation Therapy in Treating Patients with ALK-Rearranged Metastatic Lung Cancer

    This phase II trial studies how well ceritinib and stereotactic body radiation therapy work in treating patients with anaplastic lymphoma kinase (ALK)-rearranged lung cancer that has spread from the primary site (place where it started) to other places in the body (metastatic). Ceritinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and is targeted therapy, which means it targets particular abnormalities in the cancer cell, in this case ALK. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving ceritinib together with stereotactic ablative radiation therapy may be an effective treatment for lung cancer.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • Ceritinib and Everolimus in Treating Patients with Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

    This phase I trial studies the side effects and best dose of ceritinib and everolimus in treating patients with solid tumors that have spread from where they started to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic) or stage IIIB-IV non-small cell lung cancer. Ceritinib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

    The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would benefit from continued treatment with ceritinib.
    Location: See Clinical Trials.gov